Overall survival and response to radiation and targeted therapies among patients with renal cell carcinoma brain metastases.

CONCLUSIONSUse of targeted therapies in patients with RCC BM treated with intracranial SRS was associated with improved OS. However, the use of TKIs within 30 days of SRS increases the rate of radiation necrosis without improving local control or reducing distant intracranial failure. Prospective studies are warranted to determine the optimal timing to reduce the rate of necrosis without detracting from survival.
PMID: 30660120 [PubMed - as supplied by publisher]

Source: Journal of Neurosurgery - January 18, 2019 Category: Neurosurgery Authors: Juloori A, Miller JA, Parsai S, Kotecha R, Ahluwalia MS, Mohammadi AM, Murphy ES, Suh JH, Barnett GH, Yu JS, Vogelbaum MA, Rini B, Garcia J, Stevens GH, Angelov L, Chao ST Tags: J Neurosurg Source Type: research